Company Filing History:
Years Active: 2016
Title: Claudia Rossig: Innovator in Cancer Immunotherapy
Introduction
Claudia Rossig is a prominent inventor based in Heidelberg, Germany. She has made significant contributions to the field of cancer immunotherapy, particularly through her innovative work involving genetically engineered T cells.
Latest Patents
Claudia holds a patent for her invention titled "Immunotherapy of cancer using genetically engineered GD2-specific T cells." This groundbreaking invention focuses on treating cancers that express the ganglioside GD2 antigen. The patent details the use of T cells equipped with a chimeric receptor that specifically targets GD2. In particular embodiments, the chimeric receptor includes an antibody, a cytoplasmic signaling domain derived from the T cell receptor, and/or costimulatory molecules.
Career Highlights
Claudia Rossig is affiliated with the Baylor College of Medicine, where she continues her research and development in cancer therapies. Her work has been instrumental in advancing the understanding and application of immunotherapy in clinical settings.
Collaborations
Claudia has collaborated with notable colleagues, including Malcolm K. Brenner and Gianpietro Dotti, who share her commitment to improving cancer treatment through innovative research.
Conclusion
Claudia Rossig's contributions to cancer immunotherapy exemplify the impact of innovative thinking in medicine. Her work continues to inspire advancements in the treatment of cancer, showcasing the potential of genetically engineered T cells in therapeutic applications.